Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascale Missy

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 14, 2013
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort studyBenjamin Terrier, Dominique Costagliola, Sophie Prevot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.
The European Respiratory Journal|August 12, 2017
EGFR tyrosine kinase inhibitors <i>versus</i> chemotherapy in <i>EGFR</i> wild-type pre-treated advanced nonsmall cell lung cancer in daily practicePascale Tomasini, Solenn Brosseau, Julien Mazières, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2025
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2019
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France projectMichèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2017
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers FranceNicolas Guibert, Fabrice Barlesi, Renaud Descourt, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDSElisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
The European Respiratory Journal|March 17, 2018
Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm studySandrine Loubière, Alexandre Drezet, Michèle Beau-Faller, et al.
The European Respiratory Journal|February 7, 2015
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokersSébastien Couraud, Pierre-Jean Souquet, Christophe Paris, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohortAurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes (1999)|February 14, 2013
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort studyBenjamin Terrier, Dominique Costagliola, Sophie Prevot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.
The European Respiratory Journal|August 12, 2017
EGFR tyrosine kinase inhibitors <i>versus</i> chemotherapy in <i>EGFR</i> wild-type pre-treated advanced nonsmall cell lung cancer in daily practicePascale Tomasini, Solenn Brosseau, Julien Mazières, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2025
Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS"Elisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2019
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France projectMichèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2017
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers FranceNicolas Guibert, Fabrice Barlesi, Renaud Descourt, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDSElisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
The European Respiratory Journal|March 17, 2018
Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm studySandrine Loubière, Alexandre Drezet, Michèle Beau-Faller, et al.
The European Respiratory Journal|February 7, 2015
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokersSébastien Couraud, Pierre-Jean Souquet, Christophe Paris, et al.
Lung Cancer (Amsterdam, Netherlands)|December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohortAurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Pageof 3